Transaction Search Form: please type in any of the fields below.
Date: November 22, 2024 Fri
Time: 11:54 am
Time: 11:54 am
Results for medical insurance
1 results foundAuthor: Maksabedian Hernandez, Ervant J. Title: Increasing Access to Medication-Assisted Treatment for Opioid Use Disorders: Estimating Costs, Supply, and the Effects of Insurance Expansions Summary: Drug overdose deaths in America exceeded 50,000 in 2015, claiming more lives annually than gun violence and motor vehicle accidents. Of these, more than 63% of overdose deaths were due to opioids. Medication-assisted treatment is regarded as the most effective form of treatment for those struggling with an opioid use disorder. However, medication costs and insurance coverage remain identified barriers to treatment. My dissertation measures access to buprenorphine, the fastest growing form of medication-assisted treatment, and the effects of demand side interventions aiming to tackle the opioid problem in America. While some supply side interventions have mixed effectiveness or unintended consequences potentially exacerbating the problem, demand side interventions may be more effective in reducing overall demand for opioids and opioid-related deaths. Insurance expansions, such as the federal insurance parity law of 2008 or the 2014 Medicaid expansions associated with the Affordable Care Act, could have increased access to treatment. The three main insights from this dissertation are: 1) who pays for the medication matters when considering the average cost of buprenorphine maintenance treatment. Patients with public insurance have lower buprenorphine costs compared to those paying with cash-only or with commercial insurance. 2) The federal parity law for substance use disorders (MHPAEA) did not increase access to medication-assisted treatment for opioid use disorders. 3) Out-of-pocket costs for prescription opioids have decreased dramatically while costs for buprenorphine have not declined at similar pace, thus complicating access for those with an opioid use disorder. Efforts by Congress to push commercial insurers to expand coverage for addiction services have not led to lower costs for opioid treatment, unlike the experience among those with public insurance. Policymakers need to look for other ways to get commercial insurers to lower costs, particularly if further health care reform leads to a reduction in Medicaid funding and enrollment. Details: Santa Monica, CA: RAND, 2017. 125p. Source: Internet Resource: Dissertation: Accessed March 12, 2019: https://www.rand.org/pubs/rgs_dissertations/RGSD404.html Year: 2017 Country: United States URL: https://www.rand.org/pubs/rgs_dissertations/RGSD404.html Shelf Number: 154927 Keywords: Cost of InsuranceDrug Overdose DeathsMedical InsuranceOpioid EpidemicOpioidsPrescription Drug AbuseSubstance Abuse Treatment |